June 3 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REPORTS POSITIVE OVERALL RESPONSE RATE IN ITS PHASE II CLINICAL TRIAL IN 1ST LINE NSCLC FOR PD-L1 ALL-COMERS
- IMMUTEP LTD - COMBINATION OF EFTI PLUS PEMBROLIZUMAB SHOWS FAVOURABLE ANTI-TUMOUR ACTIVITY
- IMMUTEP LTD - TACTI-002 HAS MET ITS PRIMARY OBJECTIVE
- IMMUTEP LTD - OTHER SECONDARY ENDPOINTS CONTINUE TO DEMONSTRATE IMPROVEMENT ACROSS ALL PD-L1 EXPRESSION LEVELS
- IMMUTEP LTD - TACTI-002 SAFE AND WELL TOLERATED
- IMMUTEP LTD - EXPECTS TO REPORT FURTHER RESULTS FROM TACTI-002 IN H2 CALENDAR YEAR 2022
News: IMM Immutep Reports Positive Response Rate In Phase II Trial In 1st Line NSCLC For PD-L1...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $363.2M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.3¢ | $174.9K | 711.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 31418 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 234321 | 15 |
View Market Depth
| Last trade - 14.19pm 17/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |